---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-280173"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:28:33.839140+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Equillium reports Q3 net loss of $4.2M; announces $50M financing and EQ504 Phase 1 plan for mid-2026

## Summary
- Q3 2025 revenue $0 vs $12.2M in prior year; net loss $4.2M ($0.06 per share) vs $7,000 loss in Q3 2024.
- Closed private placement of up to $50M; initial $30M tranche funded by ADAR1, Janus Henderson, Adage, Coastlands, Woodline.
- Cash and investments $33.1M at Sep 30, 2025 vs $22.6M at Dec 31, 2024; expected runway through 2027.
- EQ504 (AhR modulator) for ulcerative colitis Phase 1 study expected to initiate mid-2026.

## SEC filing metadata
- accession: 0001193125-25-280173
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312525280173/0001193125-25-280173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312525280173/eq-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-280173
- JSON: https://secwatch.observer/filing/0001193125-25-280173.json
- Plain text: https://secwatch.observer/filing/0001193125-25-280173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.